https://www.selleckchem.com/pr....oducts/quinine-dihyd
For an algorithmic approach to the patient with platelet refractoriness, see Visual Abstract.The recent advent of myriad targeted therapies for acute myeloid leukemia (AML) has led to new hope for our patients but has also introduced new challenges in managing the disease. For clinicians, the ability to treat AML in the outpatient setting with novel agents of equal or greater efficacy than 7+3 has been transformative. Despite the enthusiasm, however, the reality is that many patients are still frail and remain at risk fo
Like
Comment
Share
